论文部分内容阅读
目的介绍多黏菌素的发展概况,并浅析其可能的发展方向。方法查阅国内外相关文献及市场资料。结果与结论革兰阴性菌的多药耐药问题日趋严重,目前临床仍缺乏相应的抗生素。欧美国家将六十年前的“老”抗生素———多黏菌素作为对抗革兰阴性多药耐药菌感染的最后一道防线。考虑到多黏菌素存在潜在的毒性,同时临床已分离到其抗性菌株,因此进行多黏菌素的结构修饰,以降低毒性、提高活性,成为其研究的方向之一。
Objective To introduce the development of polymyxin and to analyze its possible development direction. Methods Access to relevant literature and market information at home and abroad. Results and Conclusion The multi-drug resistance of gram-negative bacteria is becoming more and more serious. At present, there is a lack of corresponding antibiotics in clinical practice. Europe and the United States six decades ago will be “old ” antibiotics --- polymyxin as a gram-negative multi-drug resistant bacteria infection last line of defense. Taking into account the potential toxicity of polymyxin, and clinical isolates have been isolated from its resistant strains, so polymyxin structural modification to reduce toxicity and improve activity, becoming one of the directions of its research.